NAMS
NewAmsterdam Pharma Company N.V.
stock NASDAQ

> My main pause is that the drug is licensed from Amgen and I do not know the specifics of that agreement
"In 2017, Amgen decided to discontinue the internal development of obicetrapib for strategic reasons and pursue out-licensing opportunities. Forbion believes that this drug could address very substantial unmet medical needs and therefore initiated conversations with Amgen to continue developing the asset. For this purpose, it has established NewAmsterdam Pharma B.V. **Financial terms of the acquisition of obicetrapib by NAP from Amgen were not disclosed**." (https://www.businesswire.com/news/home/20200825005160/en/NewAmsterdam-Pharma-Acquires-Obicetrapib-from-Amgen)
NAMS came out of a SPAC - it's noted in the merger documents that AMGN was issued shares so I'll guess that came out of the terms of the agreement (which, given the fact that Amgen discontinued it and they were apparently non-material enough not to be mentioned in the original PR, I'll guess that the full terms of that agreement were particularly demanding.)
"What do you think about a situation like NewAmsterdam Pharma?"
I don't usually mention biotech names on here but I do own a small position in NAMS. I have a lot less in biotech than I started the year with but that's one thing that did stick around.
" Wallstreet doesn't seem too jazzed about it though."
I just feel like that's a lot of biotech over much of the last couple years. You have a set of names (a couple dozen +/-?) that are mid caps or upper end of small caps that people think will be bought and/or are doing very well that have been performing and then there's kind of ... everything else.
Not a great time for small/micro caps in a world of continued higher rates (among other issues): https://www.biospace.com/business/more-than-one-third-of-biotechs-have-under-a-year-of-cash-left-ey-finds ("More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds")

> My main pause is that the drug is licensed from Amgen and I do not know the specifics of that agreement
"In 2017, Amgen decided to discontinue the internal development of obicetrapib for strategic reasons and pursue out-licensing opportunities. Forbion believes that this drug could address very substantial unmet medical needs and therefore initiated conversations with Amgen to continue developing the asset. For this purpose, it has established NewAmsterdam Pharma B.V. **Financial terms of the acquisition of obicetrapib by NAP from Amgen were not disclosed**." (https://www.businesswire.com/news/home/20200825005160/en/NewAmsterdam-Pharma-Acquires-Obicetrapib-from-Amgen)
NAMS came out of a SPAC - it's noted in the merger documents that AMGN was issued shares so I'll guess that came out of the terms of the agreement (which, given the fact that Amgen discontinued it and they were apparently non-material enough not to be mentioned in the original PR, I'll guess that the full terms of that agreement were particularly demanding.)
"What do you think about a situation like NewAmsterdam Pharma?"
I don't usually mention biotech names on here but I do own a small position in NAMS. I have a lot less in biotech than I started the year with but that's one thing that did stick around.
" Wallstreet doesn't seem too jazzed about it though."
I just feel like that's a lot of biotech over much of the last couple years. You have a set of names (a couple dozen +/-?) that are mid caps or upper end of small caps that people think will be bought and/or are doing very well that have been performing and then there's kind of ... everything else.
Not a great time for small/micro caps in a world of continued higher rates (among other issues): https://www.biospace.com/business/more-than-one-third-of-biotechs-have-under-a-year-of-cash-left-ey-finds ("More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds")